The potential impact of new effervescent alendronate formulation on compliance and persistence in osteoporosis treatment.

Details

Ressource 1Request a copy Sous embargo indéterminé.
State: Public
Version: author
License: Not specified
Serval ID
serval:BIB_C57AFE0578AE
Type
Article: article from journal or magazin.
Collection
Publications
Title
The potential impact of new effervescent alendronate formulation on compliance and persistence in osteoporosis treatment.
Journal
Aging Clinical and Experimental Research
Author(s)
Invernizzi M., Cisari C., Carda S.
ISSN
1720-8319 (Electronic)
ISSN-L
1594-0667
Publication state
Published
Issued date
05/07/2014
Language
english
Notes
Publication types: ARTICLE
Publication Status: aheadofprint
Abstract
Osteoporotic fractures are a public health problem and their incidence and subsequent economic and social costs are expected to rise in the next future. Different drugs have been developed to reduce osteoporosis and the risk of osteoporotic fractures, and among them, antiresorptive agents, and in particular oral alendronate, are the most widely utilized. However, one of the most common problems with antiresorptive drugs is poor adherence to treatment, which is associated with a high fracture incidence and with an increase in hospitalization costs. One of the main reasons of poor adherence to these treatments is the occurrence of adverse events, mainly at gastrointestinal (GI) level, including dyspepsia, dysphagia, and esophageal ulcers. In light of these considerations the aim of this paper is to perform a literature review to show the pathophysiologic bases of GI alendronate-induced adverse events and how new bisphosphonate formulations like effervescent alendronate can improve compliance and persistence to treatment and decrease the fracture rate incidence in osteoporotic patients.
Pubmed
Create date
11/02/2015 14:56
Last modification date
15/07/2020 6:26
Usage data